Development of Small‐Molecule Antivirals for Ebola
Identifieur interne : 001488 ( Main/Exploration ); précédent : 001487; suivant : 001489Development of Small‐Molecule Antivirals for Ebola
Auteurs : Zlatko Janeba [République tchèque]Source :
- Medicinal Research Reviews [ 0198-6325 ] ; 2015-11.
Abstract
Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti‐Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small‐molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T‐705).
Url:
DOI: 10.1002/med.21355
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001212
- to stream Istex, to step Curation: 001212
- to stream Istex, to step Checkpoint: 000199
- to stream Main, to step Merge: 001490
- to stream Main, to step Curation: 001488
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of Small‐Molecule Antivirals for Ebola</title><author><name sortKey="Janeba, Zlatko" sort="Janeba, Zlatko" uniqKey="Janeba Z" first="Zlatko" last="Janeba">Zlatko Janeba</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BD393610477A8C647484BF79BD07B8E561D0B370</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/med.21355</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-7NTFDP6M-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001212</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001212</idno><idno type="wicri:Area/Istex/Curation">001212</idno><idno type="wicri:Area/Istex/Checkpoint">000199</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000199</idno><idno type="wicri:doubleKey">0198-6325:2015:Janeba Z:development:of:small</idno><idno type="wicri:Area/Main/Merge">001490</idno><idno type="wicri:Area/Main/Curation">001488</idno><idno type="wicri:Area/Main/Exploration">001488</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Development of Small‐Molecule Antivirals for Ebola</title><author><name sortKey="Janeba, Zlatko" sort="Janeba, Zlatko" uniqKey="Janeba Z" first="Zlatko" last="Janeba">Zlatko Janeba</name><affiliation wicri:level="1"><country xml:lang="fr">République tchèque</country><wicri:regionArea>Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i. Flemingovo nám. 2, CZ‐16610 Prague 6</wicri:regionArea><wicri:noRegion>CZ‐16610 Prague 6</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">République tchèque</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1175">1175</biblScope><biblScope unit="page" to="1194">1194</biblScope><biblScope unit="page-count">20</biblScope><date type="published" when="2015-11">2015-11</date></imprint><idno type="ISSN">0198-6325</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti‐Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small‐molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T‐705).</div></front></TEI><affiliations><list><country><li>République tchèque</li></country></list><tree><country name="République tchèque"><noRegion><name sortKey="Janeba, Zlatko" sort="Janeba, Zlatko" uniqKey="Janeba Z" first="Zlatko" last="Janeba">Zlatko Janeba</name></noRegion><name sortKey="Janeba, Zlatko" sort="Janeba, Zlatko" uniqKey="Janeba Z" first="Zlatko" last="Janeba">Zlatko Janeba</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001488 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001488 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BD393610477A8C647484BF79BD07B8E561D0B370
|texte= Development of Small‐Molecule Antivirals for Ebola
}}
| This area was generated with Dilib version V0.6.33. |  |